1
项与 recwt1-A10 adjuvant with AS01B 相关的临床试验Etude Phase I/II d'immunothérapie Par protéine recWT1-A10+AS01B après Greffe allogénique de Cellules Souches
Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, underwent allogeneic stem cell transplantation from HLA-identical donor (related or unrelated) after reduced-intensity conditioning regimen.
If WT1 expression is detectable on tumor cells, they will receive an immune therapy 60 days after allograft.
6 administrations every 2 weeks of the protein recwt1-A10+AS01B will be administrated.
The safety and immunological efficacy of this immune therapy after hematopoietic stem cells transplantation with reduced intensity conditioning will be evaluated.
100 项与 recwt1-A10 adjuvant with AS01B 相关的临床结果
100 项与 recwt1-A10 adjuvant with AS01B 相关的转化医学
100 项与 recwt1-A10 adjuvant with AS01B 相关的专利(医药)
100 项与 recwt1-A10 adjuvant with AS01B 相关的药物交易